BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is excited to announce a major milestone in its research and development journey. The company is transitioning its cutting-edge R&D activities to the Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. This move underscores BioNxt's commitment to scientific innovation and advancing solutions for unmet medical needs.
The new laboratory facility provides BioNxt with access to cutting-edge technologies, an expanded 1,000-square-meter research environment, and strategic opportunities for scientific collaboration within Europe's biotech hub. The transition is expected to accelerate the company's ongoing projects, particularly in the areas of drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies.
BioNxt Relocates to Gen-Plus: Strategic Importance for Advanced R&D
By leveraging the advanced and innovative infrastructure of the Gen-Plus Laboratory, BioNxt aims to harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt to:
Enhance R&D Capabilities: With access to cutting-edge equipment and analytical tools, BioNxt is better positioned to develop innovative solutions and optimize its research outcomes.
Foster Collaborations: The Munich location enables proximity to leading research institutions, biotech firms, and academic experts, paving the way for impactful partnerships.
Accelerate Innovation: The advanced resources at Gen-Plus Laboratory allow BioNxt to streamline workflows and reduce the time to bring groundbreaking therapies to market.
"BioNxt's transition to Gen-Plus marks a pivotal moment for BioNxt," said Hugh Rogers, CEO of BioNxt Solutions Inc. "This transition is both strategic and timely, and unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities that this new chapter brings, providing Impact on Current and Future projects."
BioNxt's innovative projects, including the development of advanced drug delivery systems such as sublingual thin films, transdermal patches, and other targeted therapeutic platforms, stand to gain significant advantages from the advanced capabilities at the Gen-Plus Laboratory. This cutting-edge facility is poised to accelerate preclinical research timelines, enhance formulation accuracy, and streamline the development of next-generation therapeutics.
About Gen-Plus GmbH & Co. KG
Gen-Plus GmbH & Co. KG, headquartered in Munich, Germany, is a premier Contract Research and Development Organization (CRDO) with over 25 years of experience in pharmaceutical formulation and development. The company operates a 1,000-square-meter state-of-the-art laboratory equipped for handling high-potency active pharmaceutical ingredients and licensed for GMP-compliant production, including narcotics.
Gen-Plus specializes in developing solid and semi-solid dosage forms, transdermal patches, and oral thin films, offering end-to-end services from feasibility studies to clinical trial supply production. The company leverages advanced technologies such as hot-melt extrusion, drug printing, and amorphization of APIs to deliver comprehensive pharmaceutical solutions.
Committed to innovation, Gen-Plus collaborates with leading European research institutions and biotech companies to drive advancements in pharmaceutical solutions. The company's expertise and cutting-edge infrastructure make it a trusted partner in accelerating drug development and commercialization.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is based on management's expectations, estimates, projections, and assumptions as of the date of this press release. It is subject to significant risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, general economic conditions, market conditions, regulatory risks, technological advancements, and other factors described in the Company's public disclosure filings.
Readers are cautioned not to place undue reliance on forward-looking information, as actual outcomes may differ significantly from those expressed or implied, due to various factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking information, except as required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
ZeroPath Corp. Launches Next-Generation Code Security Platform Powered by Artificial Intelligence22.1.2025 03:00:00 CET | Press release
ZeroPath Security Scanner Launches to Market, Bringing Enterprise-Grade AI Security Analysis to Development Teams SAN FRANCISCO, CA / ACCESS Newswire / January 22, 2025 / ZeroPath Corp., a Y Combinator-backed cybersecurity company, today announced the public launch of its LLM-driven code security platform. The company was previously noted for using its platform to find critical zero-day vulnerabilities in major open-source projects. Alongside the launch, the company also announced the completion of its seed funding round led by SurgePoint Capital, with Y Combinator and angel investor Paul Graham both participating. ZeroPath's security testing platform, among the first of its kind, attempts to combine deep program analysis with large language models to detect more complex security vulnerabilities. The system has previously demonstrated remarkable success in identifying critical security flaws in large open-source repositories, including remote code execution vulnerabilities, authorizati
Simpel Enters UK Market, Transforming Construction Operations From the Ground Up21.1.2025 09:00:00 CET | Press release
Delivering a unique ‘high-vis' data trail, Simpel's software empowers construction companies to optimise operations and compliance to meet the evolving regulatory environment LONDON, GB / ACCESS Newswire / January 21, 2025 / Simpel, a leading innovator in construction technology, has announced its recent entry into the UK market. Designed to address the complexities of document management, quality, compliance, safety and site access, Simpel's end-to-end platform is uniquely positioned to support construction organisations as they navigate increasing regulatory obligations and enforcement of the Building Safety Act (2022).Building Safety Act's Golden Thread of Compliance Supporting compliance of the BSA's Golden Thread Established in 2018, Simpel has matured quickly, counting many of construction's largest developers and contractors among its clients. Delivering a breadth and depth of functionality that spans a project's lifecycle, Simpel is the preferred platform for mid to large tier
The Now Corporation (OTC: NWPN) Sees Opportunities for Community Solar Projects in California21.1.2025 08:00:00 CET | Press release
PASADENA, CA / ACCESS Newswire / January 21, 2025 / The Now Corporation (OTC PINK:NWPN), an emerging leader in solar energy and utility solutions, announces its strategic focus on expanding into the California community solar market. This opportunity arises as California introduces new legislation, Assembly Bill 2316, designed to incentivize community solar projects that integrate advanced battery storage technologies. Assembly Bill 2316, recently signed into law, paves the way for broad adoption of community solar in California. The legislation benefits a wide range of stakeholders, including developers, consumers, and utility workers, while addressing the state's need for clean and reliable energy. By prioritizing projects with battery storage, California aims to shift solar power generated during the day to peak demand hours, ensuring greater grid stability and reliability. The Now Corporation, through its wholly-owned subsidiary Green Rain Solar Inc., specializes in urban solar ene
Polaris Renewable Energy Announces Q4 and Annual 2024 Financial Results Release Date and Investor Call Details20.1.2025 13:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / January 20, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q4 and annual 2024 Earnings Results on Thursday, February 20th, 2025, at 10:00 am EST. To listen to the call, please dial Toll Free 888-506-0062 or International Toll-Free Number 973-528-00-11 entry code 500570. or URL: tps://www.webcaster4.com/Webcast/Page/2773/51196 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 47795 International (toll-free): 1 919-882-2331, Passcode: 51196 Encore Replay Expiration Date: March 06, 2025 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the development, construction, acquisition, and operation of renewable energy projects in five countries in Latin Ameri
Smile Hair Clinic: Redefining Hair Transplantation in Turkey20.1.2025 01:32:00 CET | Press release
UMRANIYE, TR / ACCESS Newswire / January 20, 2025 / Smile Hair Clinic is proud to announce its position as a leader in the global hair transplant industry, offering world-class services that blend advanced medical expertise with the personalized care and affordability that Turkey is renowned for.Before After from Smile Hair Clinic Why Smile Hair Clinic? At Smile Hair Clinic, excellence is at the heart of everything we do. Our highly skilled surgeons, led by internationally recognized professionals, is dedicated to delivering natural, lasting results tailored to each patient's unique needs. Advanced Techniques for Optimal Results Smile Hair Clinic offers a range of hair restoration solutions, focusing on minimally invasive procedures that ensure quick recovery, natural-looking results. Among our most popular techniques are: FUE (Follicular Unit Extraction): This method involves extracting individual hair follicles and transplanting them to the recipient area, ensuring a seamless, scar-f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom